サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ヒト狂犬病治療の世界市場：成長、将来展望、競合分析（2022年～2030年）
市場調査レポート
商品コード
1180652

ヒト狂犬病治療の世界市場：成長、将来展望、競合分析（2022年～2030年）

Human Rabies Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 116 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
ヒト狂犬病治療の世界市場：成長、将来展望、競合分析（2022年～2030年）
出版日: 2022年08月22日
発行: Acute Market Reports
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のヒト狂犬病治療市場は、治療に対する意識の高まりや、狂犬病予防に対する政府機関の取り組みの急増といった要因により、成長が後押しされています。

当レポートでは、世界のヒト狂犬病治療市場について調査し、競合分析、マクロ分析と市場力学、製品・治療・地域別の市場分析、企業プロファイル等に関する情報を提供しています。

目次

第1章 序文

  • レポートの説明
  • 市場セグメンテーション
  • 調査手法

第2章 エグゼクティブサマリー

  • 市場スナップショット：世界のヒト狂犬病治療市場
  • 世界のヒト狂犬病治療市場：製品別、2021年（100万米ドル）
  • 世界のヒト狂犬病治療市場：治療別、2021年（100万米ドル）
  • 世界のヒト狂犬病治療市場：地域別、2021年（100万米ドル）
  • 魅力的な投資提案：地域別、2021年

第3章 ヒト狂犬病治療市場：競合分析

  • 主要なヒト狂犬病治療市場におけるベンダーの市場ポジショニング
  • ヒト狂犬病治療市場のベンダーが採用する戦略
  • 主要な業界戦略
  • 階層分析：2021年対2030年

第4章 ヒト狂犬病治療市場：マクロ分析と市場力学

  • イントロダクション
  • 世界のヒト狂犬病治療市場の金額：2020年～2030年（100万米ドル）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析

第5章 ヒト狂犬病治療市場：製品別（2020年～2030年、100万米ドル）

  • 市場概要
  • 成長と収益分析：2021年対2030年
  • 市場セグメンテーション
    • 細胞培養ワクチン
    • 狂犬病免疫グロブリン
    • 神経組織ワクチン
    • その他

第6章 ヒト狂犬病治療市場：治療別（2020年～2030年、100万米ドル）

  • 市場概要
  • 成長と収益分析：2021年対2030年
  • 市場セグメンテーション
    • 曝露前免疫
    • 曝露後予防

第7章 北米のヒト狂犬病治療市場（2020年～2030年、100万米ドル）

  • 市場概要
  • 製品別（2020年～2030年、100万米ドル）
  • 治療別（2020年～2030年、100万米ドル）
  • 地域別（2020年～2030年、100万米ドル）
    • 北米

第8章 英国・欧州連合のヒト狂犬病治療市場（2020年～2030年、100万米ドル）

  • 市場概要
  • 製品別（2020年～2030年、100万米ドル）
  • 治療別（2020年～2030年、100万米ドル）
  • 地域別（2020年～2030年、100万米ドル）
    • 英国・欧州連合

第9章 アジア太平洋のヒト狂犬病治療市場（2020年～2030年、100万米ドル）

  • 市場概要
  • 製品別（2020年～2030年、100万米ドル）
  • 治療別（2020年～2030年、100万米ドル）
  • 地域別（2020年～2030年、100万米ドル）
    • アジア太平洋

第10章 ラテンアメリカのヒト狂犬病治療市場（2020年～2030年、100万米ドル）

  • 市場概要
  • 製品別（2020年～2030年、100万米ドル）
  • 治療別（2020年～2030年、100万米ドル）
  • 地域別（2020年～2030年、100万米ドル）
    • ラテンアメリカ

第11章 中東・アフリカのヒト狂犬病治療市場（2020年～2030年、100万米ドル）

  • 市場概要
  • 製品別（2020年～2030年、100万米ドル）
  • 治療別（2020年～2030年、100万米ドル）
  • 地域別（2020年～2030年、100万米ドル）
    • 中東・アフリカ

第12章 企業プロファイル

  • Bio Med Pvt. Ltd.
  • Biological E Ltd.
  • Cadila Healthcare
  • CSC Pharmaceuticals International
  • GlaxoSmithKline GmbH
  • Grifols S.A.
  • Kamada Ltd.
  • Kedrion S.p.A.
  • Novartis International AG
  • Sanofi Pasteur SA
  • Serum institute of India
図表

List of Tables

  • TABLE 1 Global Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 2 Global Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 3 North America Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 4 North America Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 5 U.S. Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 6 U.S. Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 7 Canada Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 8 Canada Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 9 Rest of North America Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 10 Rest of North America Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 11 UK and European Union Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 12 UK and European Union Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 13 UK Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 14 UK Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 15 Germany Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 16 Germany Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 17 Spain Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 18 Spain Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 19 Italy Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 20 Italy Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 21 France Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 22 France Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 23 Rest of Europe Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 24 Rest of Europe Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 25 Asia Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 26 Asia Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 27 China Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 28 China Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 29 Japan Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 30 Japan Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 31 India Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 32 India Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 33 Australia Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 34 Australia Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 35 South Korea Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 36 South Korea Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 37 Latin America Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 38 Latin America Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 39 Brazil Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 40 Brazil Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 41 Mexico Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 42 Mexico Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 43 Rest of Latin America Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 44 Rest of Latin America Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 45 Middle East and Africa Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 46 Middle East and Africa Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 47 GCC Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 48 GCC Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 49 Africa Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 50 Africa Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Human Rabies Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Human Rabies Treatment Market: Quality Assurance
  • FIG. 5 Global Human Rabies Treatment Market, By Product, 2021
  • FIG. 6 Global Human Rabies Treatment Market, By Treatment, 2021
  • FIG. 7 Global Human Rabies Treatment Market, By Geography, 2021
  • FIG. 8 Market Geographical Opportunity Matrix - Global Human Rabies Treatment Market, 2021
  • FIG. 9 Market Positioning of Key Human Rabies Treatment Market Players, 2021
  • FIG. 10 Global Human Rabies Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 11 Global Human Rabies Treatment Market, By Product, 2021 Vs 2030, %
  • FIG. 12 Global Human Rabies Treatment Market, By Treatment, 2021 Vs 2030, %
  • FIG. 13 U.S. Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 Canada Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 Rest of North America Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 UK Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 Germany Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 Spain Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 Italy Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 France Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 Rest of Europe Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 China Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Japan Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 India Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Australia Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 South Korea Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Asia Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Brazil Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 29 Mexico Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 30 Rest of Latin America Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 31 GCC Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 32 Africa Human Rabies Treatment Market (US$ Million), 2020 - 2030
  • FIG. 33 Rest of Middle East and Africa Human Rabies Treatment Market (US$ Million), 2020 - 2030
目次
Product Code: 137704-08-22

Rabies is a fatal neurological disease, usually spread to humans through the bite of a rabid animal, and it is a persistent global problem. Factors such growing treatment awareness and rising initiatives of government organizations in prevention of rabies are primarily driving the growth of human rabies treatment market globally.

The report titled "Human rabies treatment Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" offers strategic insights into the overall human rabies treatment market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on product type, treatment type and different geographical regions.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global human rabies treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global human rabies treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global human rabies treatment market. In-depth competitive environment analysis and historical years (2021) market size data are also provided in the report.

Rabies is a life-threatening viral disease that attacks the nervous system. It is usually spread to humans via the saliva of an infected animals. The rabies virus is generally transmitted through bites and scratches from infected animals. Human rabies treatment market is categorized on the basis of product type such as cell culture vaccines, rabies immunoglobulin, nerve tissue vaccines and other. It is estimated that cell culture vaccines will show significant market growth during forecast period due to its safety, high immunogenicity, fewer adverse effects and negligible allergic reactions compared to other types of human rabies treatment. Human diploid cell strain vaccine (HDCV) is first cell culture vaccine but to overcome its higher cost, purified chicken embryo cell vaccine (PCECV) and purified vero cell culture rabies vaccine (PVRV) are available around the world by international pharmaceutical companies.

Rabies is a life-threatening illness spread via the saliva of an infected animals. The rabies virus is generally transmitted through bites and scratches from infected animals. Based treatment type, global rabies treatment market is segmented as pre-exposure immunization and post-exposure prophylaxis. It is estimated that pre-exposure immunization will show market growth during forecast period. As pre-exposure immunization is recommended for laboratory workers handling rabies and rabies related viruses, people whose activities might bring them into direct contact with animals and travelers to rabies-affected remote areas. It is studied that demand for post-exposure prophylaxis is increase in developing countries because post-exposure prophylaxis is the only safe and effective treatment available in market to prevent exposed persons from getting rabies. Post-exposure prophylaxis preferably involve management of animal bite wound, passive immunization and active immunization. According to world health organization (WHO), average cost of rabies post-exposure prophylaxis (PEP) is US$ 40 in Africa and US$ 49 in Asia. Every year, more than 15 million people worldwide receive a post-bite vaccination.

According to World health Organization (WHO), human rabies is present in 150 countries and territories and on all continents, except for Antarctica; and more than 10,000 people die each year from rabies. Globally, it is estimated that human mortality is highest in Asia, closely followed by Africa. According to Center for Disease Control and Prevention (CDC), human rabies is rare in United States with 1 to 3 cases reported annually. It is studied that, demand for pre-exposure immunization is highest in North America; United States is major regional market in North America. It is estimated that, Asia Pacific will show highest market growth during forecast period due to the increasing initiatives of government agencies and private organizations for prevention of rabies, populous countries, growing healthcare awareness and developing economic condition would expected to assist human rabies treatment market growth.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Human Rabies Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Human Rabies Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Product

Cell Culture Vaccines

Rabies Immunoglobulin

Nerve Tissue Vaccines

Others

Treatment

Pre-Exposure Immunization

Post-exposure prophylaxis

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Human Rabies Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Human Rabies Treatment market?

Which is the largest regional market for Human Rabies Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Human Rabies Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Human Rabies Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Human Rabies Treatment Market
  • 2.2. Global Human Rabies Treatment Market, By Product, 2021 (US$ Million)
  • 2.3. Global Human Rabies Treatment Market, By Treatment, 2021 (US$ Million)
  • 2.4. Global Human Rabies Treatment Market, By Geography, 2021 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2021

3. Human Rabies Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Human Rabies Treatment Market Vendors
  • 3.2. Strategies Adopted by Human Rabies Treatment Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Human Rabies Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Human Rabies Treatment Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Cell Culture Vaccines
    • 5.3.2. Rabies Immunoglobulin
    • 5.3.3. Nerve Tissue Vaccines
    • 5.3.4. Others

6. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 6.3. Market Segmentation
    • 6.3.1. Pre-Exposure Immunization
    • 6.3.2. Post-exposure prophylaxis

7. North America Human Rabies Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
  • 7.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
  • 7.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 7.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 7.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 7.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)

8. UK and European Union Human Rabies Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
  • 8.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
  • 8.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 8.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 8.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 8.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 8.4.1.4.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 8.4.1.5.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 8.4.1.6.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)

9. Asia Pacific Human Rabies Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
  • 9.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
  • 9.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 9.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 9.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 9.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 9.4.1.4.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 9.4.1.5.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 9.4.1.6.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)

10. Latin America Human Rabies Treatment Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
  • 10.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
  • 10.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 10.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 10.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 10.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)

11. Middle East and Africa Human Rabies Treatment Market, 2020-2030, USD (Million)

  • 11.1. Market Overview
  • 11.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
  • 11.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
  • 11.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 11.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 11.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
        • 11.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)

12. Company Profile

  • 12.1. Bio Med Pvt. Ltd.
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Biological E Ltd.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Cadila Healthcare
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. CSC Pharmaceuticals International
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. GlaxoSmithKline GmbH
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Grifols S.A.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Kamada Ltd.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Kedrion S.p.A.
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Novartis International AG
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Sanofi Pasteur SA
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Serum institute of India
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives